SEC Form 4 · accession 0000874015-18-000073

IONIS PHARMACEUTICALS INC · IONS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 25, 2018

Accepted (ET)

Jun 25, 2018 · 8:28 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000874015

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jun 25, 2018	M	5,700	$13.88	A	97,127	D
Common Stock^F1,F2	Jun 25, 2018	S	5,700	$42.03	D	91,427	D
Common Stock^F1	Jun 25, 2018	M	9,300	$13.88	A	100,727	D
Common Stock^F1,F3	Jun 25, 2018	S	9,300	$42.47	D	91,427	D
Common Stock^F4	holding	—	—		—	70	I	By daughter

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Director Stock Option (right to buy)	$13.88	Jun 25, 2018	M	15,000	D	Jul 1, 2012	Jun 30, 2018	Common Stock	15,000	0	D

F1Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 04/13/2018.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.76 to $42.20, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.21 to $42.815, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4The reporting person disclaims beneficial ownership of all securities held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.